Covid19COVID-19NCT05191420
Conversations You Want About Corona Virus Disease (COVID-19)
An observational study of Covid19, run by Wake Forest University Health Sciences at 1 site in United States.
Trial summary
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Covid19
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Mar 2022to 15 May 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Diverse health care professions and community members
Who may be able to join
- greater than or equal to 18 years of age
- English or Spanish speaking only
Who cannot join
- less than 18 years of age
- not English or Spanish speaking
Trial locations and contacts
1 site in 1 country.
United States1 site
Wake Forest Health Sciences
Winston-Salem, North Carolina, 27157
About this study
Official title: BECAUSE YOU MATTER: Conversations You Want About COVID-19
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level
Read the detailed description
Study will pilot test the virtual topical discussion guide with diverse health care professions and community members to confirm it is clear, relevant, understandable, and culturally appropriate
- Conditions
- Covid19
- Keywords
- Vaccines
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Virtual topical discussion guide | Study will pilot test this virtual topical discussion guide to assess feasibility and acceptability by diverse patient populations. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time spent with the guide
Time spent with the guide
Measured: Week 4
Number of clinics viewed in the guide
Number of clinics viewed in the guide
Measured: Week 4
Number of content areas accessed
Number of content areas accessed
Measured: Week 4
Time spent with each content area
Time spent with each content area
Measured: Week 4
Helpfulness of Tool
How helpful was this tool in your decision-making, ranging from 1 not at all helpful to 5 incredibly helpful
Measured: Week 4
Number of Subjects saving responses
Individuals will have the ability to send their guide responses to themselves for later use
Measured: Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2022
- Study start9 Mar 2022
- Primary completion15 May 2023
- Study completion15 May 2023
Why it stopped: unanticipated changes in environment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- More trials run by Wake Forest University Health SciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Katherine A Poehling, MD, Principal investigator, Wake Forest Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05191420
- Sponsor's protocol ID
- IRB00075790
- Acronym
- COVID-19
- Status last verified
- May 2026
- First submitted
- 11 Jan 2022
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BECAUSE YOU MATTER: Conversations You Want About COVID-19
- ClinicalTrials.gov ID
- NCT05191420
- Acronym / sponsor ID
- COVID-19 / IRB00075790
- Conditions
- Covid19
- Keywords
- Vaccines
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: unanticipated changes in environment
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Wake Forest University Health SciencesUniversity, hospital or other
- Study start
- 9 Mar 2022 (actual)
- Primary completion
- 15 May 2023 (actual)
- Study completion
- 15 May 2023 (actual)
- First posted
- 13 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level
Detailed description
Study will pilot test the virtual topical discussion guide with diverse health care professions and community members to confirm it is clear, relevant, understandable, and culturally appropriate
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Virtual topical discussion guide | – | –Study will pilot test this virtual topical discussion guide to assess feasibility and acceptability by diverse patient populations. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Diverse health care professions and community members
Key inclusion criteria (2 listed)
- greater than or equal to 18 years of age
- English or Spanish speaking only
Key exclusion criteria (2 listed)
- less than 18 years of age
- not English or Spanish speaking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time spent with the guide
Time frame: Week 4
Time spent with the guide
Number of clinics viewed in the guide
Time frame: Week 4
Number of clinics viewed in the guide
Number of content areas accessed
Time frame: Week 4
Number of content areas accessed
Time spent with each content area
Time frame: Week 4
Time spent with each content area
Helpfulness of Tool
Time frame: Week 4
How helpful was this tool in your decision-making, ranging from 1 not at all helpful to 5 incredibly helpful
Number of Subjects saving responses
Time frame: Week 4
Individuals will have the ability to send their guide responses to themselves for later use
Results and safety
The study was stopped early (reason given: unanticipated changes in environment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katherine A Poehling, MD principal investigator
Wake Forest Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by Wake Forest University Health Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: unanticipated changes in environment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time spent with the guide (time frame: Week 4). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.